Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet's disease: A multicenter study

Masaru Takeuchi; Takeshi Kezuka; Sunao Sugita; Hiroshi Keino; Kenichi Namba; Toshikatsu Kaburaki; Kazuichi Maruyama; Kei Nakai; Kuniaki Hijioka; Etsuko Shibuya; Keiko Komae; Junko Hori; Nobuyuki Ohguro; Koh Hei Sonoda; Nobuhisa Mizuki; Annabelle A. Okada; Tatsuro Ishibashi; Hiroshi Goto; Manabu Mochizuki

doi:10.1016/j.ophtha.2014.04.042

Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet's disease: A multicenter study

Masaru Takeuchi, Takeshi Kezuka, Sunao Sugita, Hiroshi Keino, Kenichi Namba, Toshikatsu Kaburaki, Kazuichi Maruyama, Kei Nakai, Kuniaki Hijioka, Etsuko Shibuya, Keiko Komae, Junko Hori, Nobuyuki Ohguro, Koh Hei Sonoda, Nobuhisa Mizuki, Annabelle A. Okada, Tatsuro Ishibashi, Hiroshi Goto, Manabu Mochizuki

Sense Organs and Rehabilitation Medicine

Research output: Contribution to journal › Article › peer-review

94 Citations (Scopus)

Abstract

Purpose: To evaluate the long-term efficacy and safety of infliximab for the treatment of uveitis in Behçet's disease (BD).

Design: Retrospective multicenter study using a questionnaire.

Participants: A total of 164 consecutive patients with BD treated with infliximab for more than 1 year were studied. The mean age at initiation of infliximab treatment was 42.6±11.7 years, and the mean treatment duration was 32.9±14.4 months.

Methods: Data before and at the last visit during infliximab treatment were analyzed in 4 groups divided by duration of treatment: group A (n = 43, 12-<24 months), group B (n = 62, 24-<36 months), group C (n = 42, 36-<48 months), and group D (n = 17, ≥48 months).

Main Outcome Measures: Best-corrected visual acuity (BCVA), relapse of ocular inflammation, numbers of ocular inflammatory attacks per year, and adverse effects of infliximab therapy.

Results: The frequency of ocular attacks decreased in all groups (from 5.3±3.0 to 1.0±0.3 in group A, 4.8±4.6 to 1.4±0.3 in group B, 4.1±2.9 to 0.9±0.3 in group C, and 9.5±5.8 to 1.6±0.5 in group D; all P < 0.05). The BCVA was improved in approximately 55% of the eyes after treatment. Mean BCVA converted to logarithm of the minimum angle of resolution was improved after treatment with infliximab in groups A to C (from 0.79±1.04 to 0.59±0.94 in group A, 0.59±1.07 to 0.41±1.04 in group B, and 1.15±1.77 to 0.92±1.73 in group C; all P < 0.05) but not in group D. Uveitis relapsed in 59.1% of all patients after infliximab treatment, and no difference in duration until relapse was observed between individual groups. Approximately 80% of relapses occurred within 1 year after the initiation of infliximab treatment in all groups, 90% of which were controlled by increasing doses of topical corticosteroids and shortening the interval of infliximab infusion. Adverse effects were observed in 65 cases or 35% of all subjects. Infliximab treatment was continued in 85% of the patients, but 15% of the patients discontinued infliximab treatment because of adverse effects or insufficient efficacy.

Conclusions: Infliximab reduced the frequency of ocular attacks and improved visual acuity in patients with BD-related uveitis and was generally well tolerated with few serious adverse events.

Original language	English
Pages (from-to)	1877-1884
Number of pages	8
Journal	Ophthalmology
Volume	121
Issue number	10
DOIs	https://doi.org/10.1016/j.ophtha.2014.04.042
Publication status	Published - 2014 Oct 1

ASJC Scopus subject areas

Ophthalmology

Access to Document

10.1016/j.ophtha.2014.04.042

Cite this

Takeuchi, M., Kezuka, T., Sugita, S., Keino, H., Namba, K., Kaburaki, T., Maruyama, K., Nakai, K., Hijioka, K., Shibuya, E., Komae, K., Hori, J., Ohguro, N., Sonoda, K. H., Mizuki, N., Okada, A. A., Ishibashi, T., Goto, H., & Mochizuki, M. (2014). Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet's disease: A multicenter study. Ophthalmology, 121(10), 1877-1884. https://doi.org/10.1016/j.ophtha.2014.04.042

Takeuchi, M, Kezuka, T, Sugita, S, Keino, H, Namba, K, Kaburaki, T, Maruyama, K, Nakai, K, Hijioka, K, Shibuya, E, Komae, K, Hori, J, Ohguro, N, Sonoda, KH, Mizuki, N, Okada, AA, Ishibashi, T, Goto, H & Mochizuki, M 2014, 'Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet's disease: A multicenter study', Ophthalmology, vol. 121, no. 10, pp. 1877-1884. https://doi.org/10.1016/j.ophtha.2014.04.042

@article{200cffec60c84f0fa6e65f94feff04ef,

title = "Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Beh{\c c}et's disease: A multicenter study",

abstract = "Purpose: To evaluate the long-term efficacy and safety of infliximab for the treatment of uveitis in Beh{\c c}et's disease (BD).Design: Retrospective multicenter study using a questionnaire.Participants: A total of 164 consecutive patients with BD treated with infliximab for more than 1 year were studied. The mean age at initiation of infliximab treatment was 42.6±11.7 years, and the mean treatment duration was 32.9±14.4 months.Methods: Data before and at the last visit during infliximab treatment were analyzed in 4 groups divided by duration of treatment: group A (n = 43, 12-<24 months), group B (n = 62, 24-<36 months), group C (n = 42, 36-<48 months), and group D (n = 17, ≥48 months).Main Outcome Measures: Best-corrected visual acuity (BCVA), relapse of ocular inflammation, numbers of ocular inflammatory attacks per year, and adverse effects of infliximab therapy.Results: The frequency of ocular attacks decreased in all groups (from 5.3±3.0 to 1.0±0.3 in group A, 4.8±4.6 to 1.4±0.3 in group B, 4.1±2.9 to 0.9±0.3 in group C, and 9.5±5.8 to 1.6±0.5 in group D; all P < 0.05). The BCVA was improved in approximately 55% of the eyes after treatment. Mean BCVA converted to logarithm of the minimum angle of resolution was improved after treatment with infliximab in groups A to C (from 0.79±1.04 to 0.59±0.94 in group A, 0.59±1.07 to 0.41±1.04 in group B, and 1.15±1.77 to 0.92±1.73 in group C; all P < 0.05) but not in group D. Uveitis relapsed in 59.1% of all patients after infliximab treatment, and no difference in duration until relapse was observed between individual groups. Approximately 80% of relapses occurred within 1 year after the initiation of infliximab treatment in all groups, 90% of which were controlled by increasing doses of topical corticosteroids and shortening the interval of infliximab infusion. Adverse effects were observed in 65 cases or 35% of all subjects. Infliximab treatment was continued in 85% of the patients, but 15% of the patients discontinued infliximab treatment because of adverse effects or insufficient efficacy.Conclusions: Infliximab reduced the frequency of ocular attacks and improved visual acuity in patients with BD-related uveitis and was generally well tolerated with few serious adverse events.",

author = "Masaru Takeuchi and Takeshi Kezuka and Sunao Sugita and Hiroshi Keino and Kenichi Namba and Toshikatsu Kaburaki and Kazuichi Maruyama and Kei Nakai and Kuniaki Hijioka and Etsuko Shibuya and Keiko Komae and Junko Hori and Nobuyuki Ohguro and Sonoda, {Koh Hei} and Nobuhisa Mizuki and Okada, {Annabelle A.} and Tatsuro Ishibashi and Hiroshi Goto and Manabu Mochizuki",

note = "Publisher Copyright: {\textcopyright} 2014 by the American Academy of Ophthalmology.",

year = "2014",

month = oct,

day = "1",

doi = "10.1016/j.ophtha.2014.04.042",

language = "English",

volume = "121",

pages = "1877--1884",

journal = "Ophthalmology",

issn = "0161-6420",

publisher = "Elsevier Inc.",

number = "10",

}

TY - JOUR

T1 - Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet's disease

T2 - A multicenter study

AU - Takeuchi, Masaru

AU - Kezuka, Takeshi

AU - Sugita, Sunao

AU - Keino, Hiroshi

AU - Namba, Kenichi

AU - Kaburaki, Toshikatsu

AU - Maruyama, Kazuichi

AU - Nakai, Kei

AU - Hijioka, Kuniaki

AU - Shibuya, Etsuko

AU - Komae, Keiko

AU - Hori, Junko

AU - Ohguro, Nobuyuki

AU - Sonoda, Koh Hei

AU - Mizuki, Nobuhisa

AU - Okada, Annabelle A.

AU - Ishibashi, Tatsuro

AU - Goto, Hiroshi

AU - Mochizuki, Manabu

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Purpose: To evaluate the long-term efficacy and safety of infliximab for the treatment of uveitis in Behçet's disease (BD).Design: Retrospective multicenter study using a questionnaire.Participants: A total of 164 consecutive patients with BD treated with infliximab for more than 1 year were studied. The mean age at initiation of infliximab treatment was 42.6±11.7 years, and the mean treatment duration was 32.9±14.4 months.Methods: Data before and at the last visit during infliximab treatment were analyzed in 4 groups divided by duration of treatment: group A (n = 43, 12-<24 months), group B (n = 62, 24-<36 months), group C (n = 42, 36-<48 months), and group D (n = 17, ≥48 months).Main Outcome Measures: Best-corrected visual acuity (BCVA), relapse of ocular inflammation, numbers of ocular inflammatory attacks per year, and adverse effects of infliximab therapy.Results: The frequency of ocular attacks decreased in all groups (from 5.3±3.0 to 1.0±0.3 in group A, 4.8±4.6 to 1.4±0.3 in group B, 4.1±2.9 to 0.9±0.3 in group C, and 9.5±5.8 to 1.6±0.5 in group D; all P < 0.05). The BCVA was improved in approximately 55% of the eyes after treatment. Mean BCVA converted to logarithm of the minimum angle of resolution was improved after treatment with infliximab in groups A to C (from 0.79±1.04 to 0.59±0.94 in group A, 0.59±1.07 to 0.41±1.04 in group B, and 1.15±1.77 to 0.92±1.73 in group C; all P < 0.05) but not in group D. Uveitis relapsed in 59.1% of all patients after infliximab treatment, and no difference in duration until relapse was observed between individual groups. Approximately 80% of relapses occurred within 1 year after the initiation of infliximab treatment in all groups, 90% of which were controlled by increasing doses of topical corticosteroids and shortening the interval of infliximab infusion. Adverse effects were observed in 65 cases or 35% of all subjects. Infliximab treatment was continued in 85% of the patients, but 15% of the patients discontinued infliximab treatment because of adverse effects or insufficient efficacy.Conclusions: Infliximab reduced the frequency of ocular attacks and improved visual acuity in patients with BD-related uveitis and was generally well tolerated with few serious adverse events.

AB - Purpose: To evaluate the long-term efficacy and safety of infliximab for the treatment of uveitis in Behçet's disease (BD).Design: Retrospective multicenter study using a questionnaire.Participants: A total of 164 consecutive patients with BD treated with infliximab for more than 1 year were studied. The mean age at initiation of infliximab treatment was 42.6±11.7 years, and the mean treatment duration was 32.9±14.4 months.Methods: Data before and at the last visit during infliximab treatment were analyzed in 4 groups divided by duration of treatment: group A (n = 43, 12-<24 months), group B (n = 62, 24-<36 months), group C (n = 42, 36-<48 months), and group D (n = 17, ≥48 months).Main Outcome Measures: Best-corrected visual acuity (BCVA), relapse of ocular inflammation, numbers of ocular inflammatory attacks per year, and adverse effects of infliximab therapy.Results: The frequency of ocular attacks decreased in all groups (from 5.3±3.0 to 1.0±0.3 in group A, 4.8±4.6 to 1.4±0.3 in group B, 4.1±2.9 to 0.9±0.3 in group C, and 9.5±5.8 to 1.6±0.5 in group D; all P < 0.05). The BCVA was improved in approximately 55% of the eyes after treatment. Mean BCVA converted to logarithm of the minimum angle of resolution was improved after treatment with infliximab in groups A to C (from 0.79±1.04 to 0.59±0.94 in group A, 0.59±1.07 to 0.41±1.04 in group B, and 1.15±1.77 to 0.92±1.73 in group C; all P < 0.05) but not in group D. Uveitis relapsed in 59.1% of all patients after infliximab treatment, and no difference in duration until relapse was observed between individual groups. Approximately 80% of relapses occurred within 1 year after the initiation of infliximab treatment in all groups, 90% of which were controlled by increasing doses of topical corticosteroids and shortening the interval of infliximab infusion. Adverse effects were observed in 65 cases or 35% of all subjects. Infliximab treatment was continued in 85% of the patients, but 15% of the patients discontinued infliximab treatment because of adverse effects or insufficient efficacy.Conclusions: Infliximab reduced the frequency of ocular attacks and improved visual acuity in patients with BD-related uveitis and was generally well tolerated with few serious adverse events.

UR - http://www.scopus.com/inward/record.url?scp=84908129409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908129409&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2014.04.042

DO - 10.1016/j.ophtha.2014.04.042

M3 - Article

C2 - 24950593

AN - SCOPUS:84908129409

SN - 0161-6420

VL - 121

SP - 1877

EP - 1884

JO - Ophthalmology

JF - Ophthalmology

IS - 10

ER -

Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet's disease: A multicenter study

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this